Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cabergoline and prolactinomas: lack of association between DRD2 polymorphisms and response to treatment.

Pituitary - 1 Jun 2017

Bueno Cbf, Trarbach E B, Bronstein M D, Glezer A

Abstract excerpt

BACKGROUND: About 80% of prolactinomas respond to dopamine agonists (DA) with hormonal normalization and tumor shrinkage. Mechanisms of DA resistance include reduction of dopamine receptor subtype 2 (DRD2) expression, short and long isoform ratio and post-receptor mechanisms. It was suggested that polymorphisms in the gene encoding dopamine receptor subtype 2 gene (DRD2) could be associated with variable...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adolescent
Share to Case-Control Studies
Share to Child

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cross-Sectional Studies

Share to Dopamine Agonists

Share to Polymorphism, Genetic

Share to Receptors, Dopamine D2

Share to Young Adult

Source

Identifiers

PMID: 27848079
DOI: 10.1007/s11102-016-0776-4

Genes

DRD2
PRL

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cabergoline and prolactinomas: lack of association between DRD2 polymorphisms and response to treatment.PMID 27848079Read ↗

Does DRD2 polymorphism influence the clinical characteristics of prolactinoma?Semantic proximity Read ↗

Pharmacogenetics of D2 dopamine receptor gene in prolactin-secreting pituitary adenomas.Semantic proximity Read ↗

Dopamine D2 receptor gene polymorphisms and response to cabergoline therapy in patients with prolactin-secreting pituitary adenomas.Semantic proximity Read ↗

Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients.Semantic proximity Read ↗

Lower PRDM2 expression is associated with dopamine-agonist resistance and tumor recurrence in prolactinomasSemantic proximity Read ↗

A Genetic Assessment of Dopamine Agonist-Induced Impulse Control Disorder in Patients With ProlactinomaSemantic proximity Read ↗

Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents.Semantic proximity Read ↗

Impact of Pharmacogenetic Markers of CYP2D6 and DRD2 on Prolactin Response in Risperidone-Treated Thai Children and Adolescents With Autism Spectrum Disorders.Semantic proximity Read ↗

Relation between serum prolactin levels and antipsychotic response to risperidone in patients with schizophrenia.Semantic proximity Read ↗

The Activation of p300 Enhances the Sensitivity of Pituitary Adenomas to Dopamine Agonist Treatment by Regulating the Transcription of DRD2Semantic proximity Read ↗

Dopamine Agonists for the Treatment of Pituitary Tumors: From Ergot Extracts to Next Generation TherapiesSemantic proximity Read ↗

UGT1A1 polymorphisms associated with prolactin response in risperidone-treated children and adolescents with autism spectrum disorder.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.